Study summary
A KRAS vaccine missed its main goal, but people with a strong immune response did much better
23.8 momedian time without relapse with the vaccine, vs 21.2 months (not a significant difference)
What was tested
Camupepimut (ELI-002 7P), a vaccine aimed at mutant KRAS, against standard follow-up care, after surgery and chemotherapy for pancreatic cancer at high risk of returning.
What they found
- Median time without relapse was 23.8 months with the vaccine vs 21.2 months with observation alone, missing the trial's main goal.
- Among vaccinated people, those who mounted a strong KRAS-specific immune response had a much lower risk of relapse (hazard ratio 0.22) than those who did not.
- Side effects were mild and no more common than with observation.
What it means
A disappointing headline result, but a clear link between immune response and outcome. The company is redesigning a phase 3 trial around people with no cancer DNA left in their blood after surgery.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.